Filing Flows › Bicycle Therapeutics (BCYC) › Q3 2026 › vs Q2 2026
Bicycle Therapeutics (BCYC) Q3 2026 vs Q2 2026 (quarter over quarter)
Bicycle Therapeutics's revenue rose $33.4M (54×) from $629K in Q2 2026 to $34.1M in Q3 2026.
Bicycle Therapeutics, Q3 2026: revenue $34.1M (+190% year over year), operating margin -39.6%, net loss $10.5M, operating cash flow −$40.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $34.1M | $629K | $33.4M | 54× |
| Other income, net | $4.2M | $4.3M | −$148K | -3% |
| Net loss | $10.5M | $50.3M | −$39.9M | -79% |
| Costs & expenses | $48.7M | $55.3M | −$6.6M | -12% |
| Operating costs | $47.5M | $55.2M | −$7.7M | -14% |
| Income tax | $1.2M | $90K | $1.1M | 13× |
| Research & development | $33.4M | $41.2M | −$7.7M | -19% |
| General & admin | $14.1M | $14.0M | $84K | +0.6% |
| Operating cash sources | $46.8M | $57.1M | −$10.3M | -18% |
| Depreciation & amortization | $1.1M | $1.1M | $6K | +0.6% |
| Share-based compensation | $5.4M | $6.4M | −$986K | -15% |
| Cash used in operations | $40.3M | $49.6M | −$9.3M | -19% |
| Net loss absorbed | $10.5M | $50.3M | −$39.9M | -79% |
| Working capital & other | $36.3M | $6.7M | $29.6M | +438% |
Questions
How much did Bicycle Therapeutics's revenue grow quarter over quarter in Q3 2026?
Bicycle Therapeutics's revenue rose $33.4M (54×) from $629K in Q2 2026 to $34.1M in Q3 2026.